Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/183848
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAguilar-Recarte, David-
dc.contributor.authorPalomer Tarridas, Francesc Xavier-
dc.contributor.authorWahli, Walter-
dc.contributor.authorVázquez Carrera, Manuel-
dc.date.accessioned2022-03-08T11:54:55Z-
dc.date.available2022-03-08T11:54:55Z-
dc.date.issued2021-08-09-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/2445/183848-
dc.description.abstractThe current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR)β/δ show promise. Remarkably, most of the antidiabetic effects of PPARβ/δ agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPARβ/δ-AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPARβ/δ-AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms22168555-
dc.relation.ispartofInternational Journal of Molecular Sciences, 2021, vol. 22, num. 16, p. 8555-
dc.relation.urihttps://doi.org/10.3390/ijms22168555-
dc.rightscc-by (c) Aguilar-Recarte, David et al., 2021-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)-
dc.subject.classificationTrastorns del metabolisme dels lípids-
dc.subject.classificationÀcids grassos-
dc.subject.classificationReceptors nuclears (Bioquímica)-
dc.subject.classificationGlucosa-
dc.subject.otherLipid metabolism disorders-
dc.subject.otherFatty acids-
dc.subject.otherNuclear receptors (Biochemistry)-
dc.subject.otherGlucose-
dc.titleThe PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec713706-
dc.date.updated2022-03-08T11:54:55Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
713706.pdf1.53 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons